We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+32.45%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$260M
AUM Growth
-$4.29M
Cap. Flow
-$19.9M
Cap. Flow %
-7.65%
Top 10 Hldgs %
66.62%
Holding
31
New
–
Increased
–
Reduced
3
Closed
2

Top Buys

No buys this quarter

Top Sells

1
ELVN icon
Enliven Therapeutics
ELVN
+$10.4M
2
ANAB icon
AnaptysBio
ANAB
+$6.65M
3
CDTX
Cidara Therapeutics
CDTX
+$1.22M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$806K
5
TRDA icon
Entrada Therapeutics
TRDA
+$805K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SKYE icon
1
Skye Bioscience
SKYE
$23.1M
$41.4M 15.93%
9,913,168
– –
TRDA icon
2
Entrada Therapeutics
TRDA
$266M
$29M 11.13%
4,308,379
-100,000
-2% -$805K
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.58B
$18.3M 7.05%
984,725
-42,986
-4% -$806K
ELVN icon
4
Enliven Therapeutics
ELVN
$3.75B
$15.5M 5.96%
772,477
-550,000
-42% -$10.4M
PHVS icon
5
Pharvaris
PHVS
$2.42B
$14M 5.4%
797,600
– –
MLTX icon
6
MoonLake Immunotherapeutics
MLTX
$1.65B
$13.3M 5.12%
282,313
– –
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$10.9M 4.2%
830,945
– –
VOR icon
8
Vor Biopharma
VOR
$968M
$10.3M 3.96%
318,086
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$1.99B
$10.3M 3.96%
736,595
– –
TECX
10
Tectonic Therapeutic
TECX
$613M
$10.2M 3.91%
511,660
– –
CLDX icon
11
Celldex Therapeutics
CLDX
$2.74B
$10.1M 3.89%
497,270
– –
EYPT icon
12
EyePoint Inc
EYPT
$1.13B
$9.88M 3.8%
1,050,000
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.95B
$8.99M 3.46%
939,298
– –
PRAX icon
14
Praxis Precision Medicines
PRAX
$8.82B
$7.15M 2.75%
170,000
– –
GHRS icon
15
GH Research
GHRS
$1.99B
$6.98M 2.68%
572,665
– –
ERAS icon
16
Erasca
ERAS
$6.64B
$6.86M 2.64%
5,405,404
– –
BHVN icon
17
Biohaven
BHVN
$2.3B
$6.76M 2.6%
478,972
– –
VKTX icon
18
Viking Therapeutics
VKTX
$4.27B
$5.02M 1.93%
189,593
– –
SCPH
19
DELISTED
scPharmaceuticals
SCPH
$4.57M 1.76%
1,200,647
– –
CAMP icon
20
CAMP4 Therapeutics
CAMP
$185M
$4.25M 1.63%
2,927,915
– –
ARTV
21
Artiva Biotherapeutics
ARTV
$472M
$3.55M 1.37%
2,353,304
– –
SRZN icon
22
Surrozen
SRZN
$246M
$2.77M 1.07%
310,000
– –
SLN
23
Silence Therapeutics
SLN
$510M
$2.76M 1.06%
476,200
– –
TARA icon
24
Protara Therapeutics
TARA
$232M
$2.42M 0.93%
800,000
– –
ALEC icon
25
Alector
ALEC
$163M
$1.39M 0.54%
995,841
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
BWM
BNC Wealth Management Beaverton, Oregon $360M AUM 49.82% 1-Year Est. Return
LC
Legacy CG Plano, Texas $360M AUM 17.55% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
PWM
Proathlete Wealth Management Boca Raton, Florida $361M AUM 17.13% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return

5AM Venture Management's Q2 2025 Portfolio in Review

As of Q2 2025, 5AM Venture Management held 31 positions worth $260M, down 1.6% from $264M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

5AM Venture Management withdrew a net $19.9M in Q2 2025, closing 2 positions and reducing 3 holdings. Its most notable exit was AnaptysBio, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's biggest Q2 2025 reduction was Enliven Therapeutics, cutting an estimated $10.4M.
  • 5AM Venture Management fully exited AnaptysBio in Q2 2025, selling an estimated $6.65M.
  • 5AM Venture Management's ten largest holdings make up 67% of its $260M portfolio in Q2 2025.
  • 5AM Venture Management opened 0 new positions and closed 2 in Q2 2025.
  • 5AM Venture Management's portfolio value fell 1.6% quarter-over-quarter to $260M.

Based on 5AM Venture Management's 13F filing for Q2 2025, filed 14 Aug 2025.